youtube_live
Q2 2027 earnings • released • Revenue beat +5.10%
See resultschevron_right
4523:TYO
Eisai Co Ltd
¥5,206.00
arrow_upward
+0.70%(+36.00) 1D
Nov 13, 2:36:07 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4523...
Open
¥5,152
High
¥5,216
Low
¥5,093
Mkt. cap
1.52T
Avg. vol.
1.35M
Volume
1.07M
Dividend
3.07%
Quarterly dividend
¥40
Ex-dividend date
Sep 29, 2026
P/E ratio
33.46
52-wk high
¥5,284
52-wk low
¥3,660
EPS
¥156
Shares outstanding
286.43M
No. of employees
11K
Open
¥5,152
High
¥5,216
Low
¥5,093
Mkt. cap
1.52T
Avg. vol.
1.35M
Volume
1.07M
Dividend
3.07%
Quarterly dividend
¥40
Ex-dividend date
Sep 29, 2026
P/E ratio
33.46
52-wk high
¥5,284
52-wk low
¥3,660
EPS
¥156
Shares outstanding
286.43M
No. of employees
11K
News stories
From web sources and news partners
Yahoo Finance
·
6 hours ago
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
Seeking Alpha
·
6 hours ago
Eisai Co., Ltd. 2027 Q2 - Results - Earnings Call Presentation (OTCMKTS:ESAIY) 2026-11-12
finance.biggo.com
·
1 day ago
[Eisai FY2026 Q2 Earnings Call] Eisai Posts 20.4% Rise in Interim Operating Profit to ¥41.4 Billion - Subcutaneous Leqembi Winning Patients at 4x the Pace of IV; Full-Year ¥70 Billion Target "Aiming for Upside"
Investing.com
·
2 days ago
Eisai Q2 FY2026 slides: 3L products drive 17.5% revenue growth
Profile
Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices. Wikipedia
About Eisai Co Ltd
CEOHaruo Naito | Haruo Naito
Employees10.5K
FoundedDec 6, 1941
HeadquartersBunkyo City, Tokyo, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websiteeisai.co.jp